Medical Oncology

Doç. Dr. Yakup İriağaç

Doctor and researcher Balıkesir Atatürk Şehir Hastanesi Balıkesir
Breast NeoplasmsLung NeoplasmsCarcinoma, Non-Small-Cell LungNeoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 12 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lung Neoplasms 6 publications
  • Carcinoma, Non-Small-Cell Lung 4 publications
  • Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionBalıkesir Atatürk Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 12 publications · Model version —From source
  • Publications51 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0001-7411-1705ORCIDFrom source
  • Last synchronised5 November 2026 07:37https://balikesirataturksehir.saglik.gov.tr/TR-677864/doktorlarimiz.html#yakup-iriagacsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

51 publications

  1. Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15805-w PMID 41749167 Open-access full textSource: ORCID

  2. Analysis of prognostic factors in metastatic colon cancer

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1803902 Open-access full textSource: ORCID

  3. The impact of exercise prehabilitation on upper extremity range of motions, functionality and quality of life in breast cancer survivors: a prospective clinical trial

    BMC Sports Science, Medicine and Rehabilitation, 2026

    DOI 10.1186/s13102-026-01534-x PMID 41612417 Open-access full textSource: ORCID

  4. Survival Impact of Adjuvant Chemoradiotherapy in Resected Pancreatic Cancer

    Namık Kemal Tıp Dergisi, 2025

    DOI 10.4274/nkmj.galenos.2025.81994 Open-access full textSource: OpenAlex

  5. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  6. Prognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole

    Bratislava Medical Journal, 2025

    DOI 10.1007/s44411-025-00237-y Open-access full textSource: ORCID

  7. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Clinical Breast Cancer, 2025

    DOI 10.1016/j.clbc.2025.03.003 PMID 40190010 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  8. The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer

    Medicine, 2025

    DOI 10.1097/md.0000000000044743 PMID 41029123 1 citation (Europe PMC) Open-access full textSource: ORCID

  9. Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?

    Revista da Associação Médica Brasileira, 2025

    DOI 10.1590/1806-9282.20250507 PMID 41124552 Open-access full textSource: ORCID

  10. Spectrum of BRCA1 and BRCA2 Variants in Breast Cancer Cases: A Single-Center Experience

    DergiPark (Istanbul University), 2025

    Source: OpenAlex

View all 51 publications